- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Emerging Insights on MRI-Guided Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer
In a recent video interview, Amar Kishan, M.D., discussed a new study that demonstrated significant side effect reduction when utilizing magnetic resonance imaging (MRI) guidance instead of computed tomography (CT) guidance for stereotactic body radiation therapy (SBRT) to treat localized prostate cancer.
Emerging research suggests that magnetic resonance imaging (MRI) guidance may be more advantageous than computed tomography (CT) guidance for reducing the side effects of stereotactic body radiation therapy (SBRT) in the treatment of prostate cancer.
Results from the phase 3 randomized trial, recently published in JAMA Oncology, showed that MRI guidance for SBRT led to a significantly reduced acute grade 2 or greater genitourinary (GU) toxicity rate (24.4 percent) versus that of CT guidance (43.4 percent). Researchers also noted no acute grade 2 or greater gastrointestinal (GI) toxic effects with MRI guidance in comparison to a 10.5 percent toxicity rate for CT guidance.
In a recent video interview, lead study author Amar Kishan, M.D. called the MRIdian LINAC (ViewRay) a “major technological breakthrough” that allows physicians to combine continuous MRI imaging with a more targeted radiation delivery system for prostate cancer.
“(With) these advanced precision and accuracy capabilities, particularly that high degree of tracking during the treatment, we felt we could reduce the margins around the prostate that we need to treat from four millimeters to two millimeters,” explained Dr. Kishan, an associate professor, vice-chair of Clinical and Translational Research and chief of the Genitourinary Oncology Service within the Department of Radiation Oncology at UCLA.
For more insights from Dr. Kishan, watch the video below.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Can AI Enhance PET/MRI Assessment for Extraprostatic Tumor Extension in Patients with PCa?
December 17th 2024The use of an adjunctive machine learning model led to 17 and 21 percent improvements in the AUC and sensitivity rate, respectively, for PET/MRI in diagnosing extraprostatic tumor extension in patients with primary prostate cancer.
What SPECT/CT May Reveal About Early Treatment Response for Pluvicto in Patients with mCRPC
November 13th 2024Researchers found that new prostate lesion detection on SPECT/CT at the beginning of a second cycle of 177 Lu-PSMA-617 for mCRPC was associated with an over sevenfold higher mortality risk.
AI Segmentation, Intraprostatic Tumor Volume and Metastases: What a New mpMRI Study Reveals
October 29th 2024For patients who received radiotherapy for localized prostate cancer, total intraprostatic tumor volume derived from AI segmentation had a 10 percent higher AUC for predicting seven-year metastases in comparison to a risk model from the National Comprehensive Cancer Network (NCCN).
